人偏肺病毒融合蛋白疫苗研究进展  

Research progress in human metapneumovirus fusion protein vaccines

作　　者：王怡丹 李智华 毕研伟 李倩倩 Wang Yidan;Li Zhihua;Bi Yanwei;Li Qianqian(Key Laboratory of Pathogen Infection Prevention and Control(Peking Union Medical College),Ministry of Education,Institute of Medical Biology,Chinese Academy of Medical Sciences,Kunming 650031,China;School of Life Sciences,Yunnan University,Kunming 650091,China)

机构地区：[1]中国医学科学院医学生物学研究所,病原体感染防控教育部重点实验室(北京协和医学院),昆明650031 [2]云南大学生命科学学院,昆明650091

出　　处：《中华微生物学和免疫学杂志》2024年第7期608-613,共6页Chinese Journal of Microbiology and Immunology

摘　　要：人偏肺病毒是一种常见的呼吸道病毒,属肺炎病毒科偏肺病毒属,2001年首次发现于荷兰,全球广泛分布,能够反复感染婴幼儿、老年人及免疫功能低下者,并引起急性呼吸道感染。目前,尚无有效的预防性疫苗批准上市。本文主要概述人偏肺病毒的病毒学和流行病学特征,介绍其潜在疫苗关键免疫原融合蛋白的结构和抗原位点,以及基于融合蛋白设计的亚单位疫苗、减毒活疫苗和核酸疫苗研究的最新进展。Human metapneumovirus,first identified in the Netherlands in 2001,is a common respiratory virus belonging to the genus Metapneumovirus of the family Pneumoviridae.It has spread across the world.It can cause repeat infections in infants,young children,the elderly,and immunocompromised people,and lead to acute respiratory infections.There are currently no effective prophylactic vaccines approved for marketing.This article mainly focuses on the virological and epidemiological characteristics of human metapneumovirus,introduces the structure of fusion protein,a potential key immunogen for vaccine development,and the antigenic loci on fusion protein,and summarizes the research progress in subunit vaccines,live attenuated vaccines,and nucleic acid vaccines designed based on fusion protein.

关 键 词：人偏肺病毒 疫苗 融合蛋白 抗原设计 

分 类 号：R392[医药卫生—免疫学]